Inclusion Criteria:

          -  Adult subjects; age ≥ 18

          -  Written and signed informed consent must be obtained

          -  Have histologic or cytologic documentation of solid tumor including EGFR mutated
             (EGFRm) NSCLC

          -  Subjects must have at least 1 lesion that is measureable using RECIST guidelines

          -  Subjects must consent to provide archived tumor specimens or tumor biopsies for
             correlative biomarker studies.

          -  Eastern Cooperative Oncology Group performance score of 0 or 1

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior treatment with tumor necrosis factor receptor superfamily agonists including
             OX40, CD27, CD137 (4-1BB), CD357 (GITR). One cohort also excludes anti CTLA-4, anti
             PDL-1 and anti PDL-1.

          -  Subjects who have received prior therapy with regimens containing CTLA-4, PD-L1, or
             PD-1 antagonists may be permitted to enroll under certain conditions

          -  Cardiac or peripheral vascular disease meeting any of the following criteria:

               -  Past history of myocardial infarction in the prior 12 months

               -  Past history of stroke or transient ischemic attack requiring medical therapy

               -  Congestive heart failure ≥ Class 3 based on New York Heart Association Functional
                  Classification

          -  Grade 3 or greater edema (eg, peripheral, pulmonary)

          -  History of Grade 3 or greater thromboembolic events in the prior 12 months

          -  Subjects with active tuberculosis are ineligible. In settings where there is clinical
             or radiographic evidence of tuberculosis, active disease must be ruled out

          -  Active or prior documented autoimmune or inflammatory disorders

          -  Untreated central nervous system (CNS) metastatic disease

          -  Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B
             or active hepatitis A or C

          -  Other invasive malignancy within 2 years except for noninvasive malignancies such as
             cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the
             skin, ductal carcinoma in situ of the breast that has been surgically cured

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, active peptic ulcer disease or gastritis, uncontrolled hypertension,
             uncontrolled diabetes, or psychiatric illness/social situations that would limit
             compliance with study requirement